The Prostate Cancer Foundation has announced a $6.3 million investment to support 31 early-career scientists through its 2025 Young Investigator Awards, reinforcing its long-standing commitment to advancing precision medicine and life-extending treatments for prostate cancer patients worldwide.
The funding will back a new class of researchers pursuing innovative discoveries in prostate cancer diagnosis, treatment, and care. Since launching its early-career awards program in 1993, the foundation has provided more than $100 million in research funding to over 500 young scientists across 17 countries, pairing financial support with mentorship to accelerate clinical innovation.
The 2025 awards cycle drew 151 applications from researchers at institutions in 14 countries. More than 185 expert reviewers evaluated submissions to identify 31 standout investigators whose work aims to uncover new therapeutic targets, expand precision oncology approaches, and apply cutting-edge technologies to improve patient outcomes. According to PCF, private philanthropic funding plays a critical role in advancing these researchers’ promising ideas.
Over the years, the program has helped cultivate leaders in the field whose work has led to major advances. Alumni include researchers behind the first genomic sequencing and precision oncology platform for prostate cancer, the first FDA-approved PSMA PET imaging agents, and expanded genetic testing programs for inherited prostate cancer risk genes. This year’s cohort also includes the first-ever PCF Young Investigator based in France, highlighting the initiative’s growing global reach.
Founded in 1993 by Mike Milken, PCF describes itself as the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. The foundation says it has raised more than $1 billion to support over 2,615 research projects at 312 leading cancer centers across 29 countries. Through its funding and collaborative model, PCF aims to reduce mortality, extend survival, and improve quality of life for patients worldwide.
KEY QUOTE:
“Every breakthrough begins with a brilliant mind and a bold new idea. Our new class of PCF Young Investigators represent the next generation of visionary leaders in prostate cancer research and treatment. Through dedicated funding and mentorship, this program attracts the world’s best minds to the field and enables them to advance precision medicine, uncover new therapeutic targets, and harness cutting-edge technologies that will save and improve lives for decades to come.”
Gina Carithers, President and CEO, Prostate Cancer Foundation
